Review Point Explainer: Prescribing Information Placement in Medical Content Materials

A valid PI check asks more than whether a final page exists. It verifies the information, the product, and the distribution context.

A prescribing information check can look deceptively simple: find the PI page, confirm it is present, and move on.

In practice, that approach misses the real review question.

A medical content material can fail a PI check in at least three different ways. The required information may be missing. The material may point to prescribing information for the wrong product. Or product information may appear in a material, audience, or channel where company rules require a different treatment.

These are not equivalent problems, and they cannot be resolved by asking whether the deck contains the words "prescribing information" or a QR code.

PI review is a combined check of presence, product identity, material context, and distribution rules.

The regulatory requirement is contextual

Prescribing information and risk-disclosure obligations vary by jurisdiction, format, audience, and communication type.

For example, the U.S. Food and Drug Administration explains that prescription drug advertisements must include specified risk information, with different mechanisms for print and broadcast formats. The FDA also distinguishes full Prescribing Information from the "brief summary" used in advertising contexts. In the European Union, Directive 2001/83/EC requires advertising to healthcare professionals to include essential information compatible with the product's summary of product characteristics, while also setting different limits for advertising prescription-only medicines to the general public.

The operational lesson is not that one global rule applies everywhere. It is the opposite: review logic must be configured to the relevant market, material type, audience, channel, and company SOP.

That is why a reliable pre-review system should not make a legal conclusion from page appearance alone. It should surface the relevant evidence and help the accountable reviewer apply the correct rule set.

Risk 1: Required PI is missing or not reviewably accessible

The first failure mode is omission.

A material that requires prescribing information may contain no PI page, no approved link or QR route, and no other reviewable way to access the applicable information. This is the most visible risk, but even here a simple search can mislead.

A deck may mention "prescribing information" in a table of contents, a training instruction, or a workflow note without actually providing the required content. A QR code may lead to a corporate account, survey, event registration page, or general website rather than the correct approved PI.

The review therefore needs to answer more than "Was something found?" It should ask:

• Is there a genuine PI page or an approved access mechanism?
• Is the destination available and reviewable?
• Does it correspond to the relevant market and current approved version?
• Does the material type require it under the applicable SOP?

The difference between a keyword hit and valid evidence is the difference between search and review.

Risk 2: The PI belongs to the wrong product

The second failure mode is mismatch.

This often appears when teams reuse an existing deck, copy a final slide from another material, or update the main content without updating the PI attachment. The deck may contain a plausible PI page, but the generic name, brand name, dosage form, or approved destination belongs to a different product.

This is particularly easy to miss during manual review because the page may look familiar and complete. A reviewer who only confirms presence may not compare the PI identity with the product discussed across the rest of the material.

A stronger check creates a product-consistency loop:

1. Identify the likely PI page.
2. Extract the generic name, brand name, dosage form, or product identifier.
3. Identify the material's core product or product line.
4. Compare the two using the applicable company rules.
5. Present any mismatch with page-level evidence for human review.

The resulting flag should be specific: which product the material appears to discuss, which product the PI appears to describe, and where each signal was found.

Risk 3: PI appears in the wrong material or distribution context

The third failure mode is inappropriate exposure.

Some materials are intended for healthcare professionals. Others are scientific-exchange, disease-education, patient-education, internal-training, or public-facing materials. The same product information element may be appropriate in one context and inappropriate, unnecessary, or subject to a different rule in another.

That means a PI page cannot be assessed separately from the material classification and intended audience.

For example, a reviewer may need to confirm:

• whether the material is promotional, scientific, educational, or internal;
• whether it is intended for healthcare professionals, patients, or the general public;
• whether the market permits the relevant type of product communication;
• whether the PI mechanism is required, optional, exempted, or restricted;
• whether an approved text version, approved QR destination, or another format is acceptable under the company's SOP.

This is a routing and policy question as much as a content question. AI can help collect and connect the signals, but the final determination remains with qualified reviewers.

Why keyword and QR-code checks create false confidence

Keyword matching is useful for retrieval, but weak as a final decision rule.

Searching for "prescribing information" can return a contents page, training slide, disclaimer, or discussion of PI requirements. Searching for QR codes can return social-media, survey, event, or educational links. Page position is also only a clue: PI often appears near the end, but "near the end" does not prove identity or validity.

The same limitation applies to visual similarity. A dense page with legal-looking text may be a disclaimer or clinical guideline. A clean QR page may provide approved PI access—or may point somewhere unrelated.

Each signal becomes useful when combined. None is reliable enough on its own.

How ZENO supports PI review before formal MLR approval

ZENO is designed to support review teams by turning PI checks into a structured, human-reviewable workflow.

The workflow can combine:

• page-level candidate retrieval based on title, position, text structure, visual elements, and QR-code presence;
• OCR and document parsing for text embedded in images or screenshots;
• product-name and dosage-form extraction;
• verification against company-specific SOP conditions and exclusion rules;
• cross-document comparison between the PI candidate and the material's core product;
• material-type, audience, market, and channel rules;
• page location, matched evidence, risk explanation, and routing for human review.

Instead of returning a black-box "pass" or "fail," the system should explain what it found and what needs confirmation.

A useful output might say:

A likely PI page was found on slide 42. The page references Product B, while the main material repeatedly references Product A. Please confirm whether the correct approved PI has been attached.

A QR-code page was found, but the destination could not be verified as the approved PI source for the identified product and market. Human review is required.

These outputs do not make the final regulatory decision. They make the decision point visible earlier.

What should remain human

Qualified reviewers should continue to determine:

• which jurisdictional and company rules apply;
• how the material should be classified;
• whether the audience and distribution context are appropriate;
• whether a PI version or QR destination is approved and current;
• whether an exception or exemption applies;
• whether the material may proceed, requires correction, or needs escalation.

The role of AI-assisted review is to reduce the search burden, connect evidence across the material, and make potential inconsistencies easier to evaluate.

From "Is it there?" to "Is it correct here?"

The most useful PI review question is not simply whether the deck includes a final page.

It is whether the correct prescribing information is present, connected to the correct product, appropriate for the material and audience, aligned with the applicable SOP, and supported by evidence a reviewer can inspect.

That shift—from presence to contextual correctness—is what turns PI checking from a formatting task into a meaningful MLR pre-review capability.